Health Affairs October 22, 2024
Colleen Campbell

The Food and Drug Administration’s approval of nearly a dozen gene therapies in the past year, including milestone treatments for sickle cell disease and hemophilia B, has finally ushered in the era of precision medicine. Yet, the United States remains unprepared to welcome this new chapter in health care.

The barriers to the full adoption of precision medicine are not confined to prohibitive costs, insurance complexities, and other expected health care system hurdles. An undervalued factor in the uptake of precision medicine is the system’s capability to connect patients to treatment. This is hindered by insufficient access to genetic health care in the United States, where genetic counselors play a leading role. For example, there is fewer than one full-time...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Oncologist talks personalized medicine for pancreatic cancer
AI offers a step above genomic solutions
How Mayo Clinic is using real-world data to advance precision medicine
Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Share This Article